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proposing a deﬁnition of structural progression and a deﬁnition of
unacceptable symptom state.
Methods: The group in charge of the “unacceptable symptom
state” ﬁrst decided to focus on 2 domains e.g. pain and functional
impairment, second to propose new tools for evaluating such
domains, and third to conduct a cross sectional study in order to
propose a threshold of the value in such tools above which the
level of symptoms will be considered as not acceptable. For such
purpose, the opinion of the orthopedists concerning their visiting
patients (e.g. good candidate for total articular replacement yes/no)
was considered as the gold standard.
Results: An OARSI-OMERACT pain tool and an OARSI-
OMERACT function hip/knee tools have been elaborated [1–3].
The study aimed at proposing a threshold in such tools for deﬁn-
ing a non acceptable symptom state has recruited more than 2000
patients in more than 10 different countries.
Conclusions: Such joint OARSI-OMERACT initiative should facil-
itate the conduct of clinical trials to more accurately evaluate not
only symptomatic but also disease modifying treatments.
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The prevalence of primary osteoarthritis (OA) increases with age.
Aging, therefore, represents a major risk factor for OA. Cartilage
degradation is most certainly not simply an effect of wear and
tear processes but is signiﬁcantly inﬂuenced by molecular reg-
ulatory systems. However, the degree to which regulated aging
processes are responsible for the loss of tissue function in OA is
not yet fully resolved. Several experimental ﬁndings are consistent
with a senescent-like state of arthritic chondrocytes and cartilage.
These include a shortening of the telomere ends, the expression
of senescence markers like SA-βgal, altered cytokine expression
proﬁles and age-dependent modiﬁcations of the extracellular ma-
trix. Our own results show an increased transcriptional noise and
elevated DNA damage levels in OA chondrocytes.
The process of aging is not an unregulated process but is
regulated by evolutionary conserved pathways that safeguard
the maintenance of cellular homeostasis. The deregulation of
these regulatory networks is linked to the development of aging-
associated diseases. In this respect, perturbations of the so-
matotrophic axis (GH-IGF-Akt) are of special interest. Mice with
reduced IGF-1 and insulin signaling (Ames and Snell dwarf mice,
Klotho-overexpressing mice) live signiﬁcantly longer than littermate
mice and show an overall reduction of aging-related pathological
changes. Interestingly, long-lived Snell dwarfs (which do not pro-
duce growth hormone) show a delay of articular cartilage aging
and do not develop OA at an age when up to 58% of their wild-type
littermates already do.
Our own research provides evidence for a major perturbation of
the IGF-Akt-FoxO signaling pathway in human osteoarthritic knee
cartilage with reduced FoxO expression levels and an overall
reduction of the expression of important stress-response genes
concomitant with higher cellular damage levels. The transcript
levels of all four known FoxO genes, FoxO1, FoxO3a, FoxO4
and FoxO6 were signiﬁcantly reduced in the osteoarthritic tissue.
This decrease was more pronounced in late osteoarthritic carti-
lage compared with early degenerated tissues. Several important
FoxO target genes were substantially deregulated. The cell cycle
regulators p21, p27 and cyclin G2 were signiﬁcantly downregu-
lated, while cyclin D1 was markedly upregulated, corresponding
to the downregulation of FoxO levels. The FoxO regulated genes
involved in oxidative defense also showed differential regulation.
The expression of SOD genes was substantially reduced in OA,
with SOD2 showing the most substantial decline. mRNA levels of
GADD45, a gene involved in DNA repair, were markedly lower in
osteoarthritic tissue.
The emerging insights into the mechanisms underying general ag-
ing processes promise to open up new avenues for drug discovery.
The identiﬁcation of pharmacologically tractable drug targets within
these conserved aging pathways will make it possible to develop
novel therapeutic options for age-related diseases, including pri-
mary osteoarthritis. We expect, therefore, that further insights on
the role of natural aging processes in the development and pro-
gression of primary osteoarthritis, and thus a better understanding
of the processes underlying cartilage aging and degradation, will
translate into novel ideas and ways of preventing and treating OA.
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An opportunity to detect early stages of process leading to clinical
osteoarthritis (OA) is offered by the emerging molecular marker
technology. This development will be further advanced when mark-
ers with spatial, temporal and process speciﬁcity become available.
Molecular markers have the potential to provide information the
relative activity of the process of degradation and repair attempts,
including an inadequate tuning of the synthesis of new constituents
of the matrix.
markers with apparent tissue speciﬁcity: There are a number of
molecules that are released from cartilage as a result of the local
process. These include aggrecan, where the fragments containing
the chondroitin sulfate chains appear early in disease and are
formed also in the normal tissue turnover. The ﬁne structure of
the glycosaminoglycan side chains change both with age and in
disease.
The G1 hyaluronan binding domain is initially retained in the tissue
bound to hyaluronan to be released in late stage tissue injury.
Cleavage of Aggrecan at several speciﬁc sites by ADAMTS-family
members provides unique cleavage sites and neo-epitope anti-
bodies only recognizing fragments with an end corresponding the
cleavage are available and applied to studies of joint disease.
Collagen type II epitopes studied include those of the telopeptides
at the ends of the molecule and those from cleavages of the
triple helical region. Applications of these assays demonstrate
increased release of fragmented collagen in osteoarthritis. There
are discussions on the speciﬁcity of some of these assays.
New synthesis of collagen can be detected by the production and
release of the propeptides cleaved of the precursor procollagen II.
Such assays have been employed in studies of collagen synthesis
in joint disease.
Spatial speciﬁcity is possible to obtain by using proteins which are
present in only a given tissue compartment.
Interterritorial distribution: Examples of such proteins are CILP
and COMP. Both occur preferentially in the interterritorial matrix
of the adult articular cartilage.
COMP is released at an early stage of joint disease. Accordingly
elevated COMP levels may serve as a predictor of destruction of
the cartilage identiﬁed by imaging years later. One shortcoming
of many of currently employed assays, including for COMP, is
the background provided by turnover in normal cartilages. As a
